Report reveals CMOs in Italy concentrated in worst-hit COVID-19 regions
According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.
List view / Grid view
According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.
Researchers have begun research to find how sustainable cold chain delivery systems for a COVID-19 vaccine can be established in resource-poor countries.
In light of the COVID-19 pandemic, WHO has asked the pharmaceutical supply chain to swiftly distribute nets and antimalarial medicines in sub-Saharan Africa.
The ABPI's Dr Richard Torbett, speaking to the International Trade Committee, said the COVID-19 pandemic highlights the need for a globalised drug supply chain.
Dr Abhishek Dadhich rounds up how the Indian pharmaceutical market has been impacted by the coronavirus pandemic and the steps the country’s government could take to overcome these setbacks.
The European Medicines Agency (EMA) and other authorities have created a new shortage reporting system and are looking into how regulations can be applied more flexibly during the COVID-19 pandemic.
Dr Sam Roscoe explains his recommendations for pharmaceutical companies and supermarkets in the UK to limit reliance on deliveries from overseas, to ease the impact of the COVID-19 coronavirus on drug supply chains.
An open letter from doctors highlights that although chloroquine and hydroxychloroquine are strong candidates to fight COVID-19, there is a limited supply.
With concerns rising about medicine availability during the global COVID-19 coronavirus pandemic, European Pharmaceutical Review explores how the pharmaceutical supply chain is faring.
The European Medicines Agency (EMA) has advised consumers on how to recognise registered online pharmacies so they can avoid falsified medications.
The presence of female directors makes boards more likely to report lower-severity defects and faster to recall products with high-severity problems, suggests research.
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
The survey indicates that almost all respondents were concerned about the COVID-19 pandemic’s effects on company performance, including supply and demand failures.
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
Having become aware of insulin shortages in pharmacies, the company has stated that its products are not backordered and should be available for delivery by wholesalers.